Government-Owned Inventions; Availability for Licensing, 66685 [2019-26278]

Download as PDF Federal Register / Vol. 84, No. 234 / Thursday, December 5, 2019 / Notices and pandemic-potential influenza viruses. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404. Potential Commercial Applications: DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Jenish Patel, Ph.D., 240–669–2894; jenish.patel@nih.gov. Licensing information and copies of the U.S. patent application listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. jbell on DSKJLSW7X2PROD with NOTICES SUMMARY: Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses Description of Technology: There is a great need for broadly protective, ‘‘universal’’ influenza virus vaccines given the antigenic drift and shift of influenza viruses and the variable protective efficacy of the current influenza vaccines. This technology relates to a broadly protective, ‘‘universal’’ influenza vaccine candidate composed of a cocktail of different low pathogenicity avian influenza virus subtypes inactivated by betapropiolactone (BPL). Vaccinating animals with BPL-inactivated whole virus vaccine comprising influenza virus strains belonging to four or more different low pathogenicity avian influenza hemagglutinin subtypes, intranasally or intramuscularly, provided extremely broad protection and heterosubtypic protection to lethal challenge with influenza viruses in both mice and ferrets. This influenza vaccine technology has a great potential to offer broad protection against both seasonal VerDate Sep<11>2014 17:38 Dec 04, 2019 Jkt 250001 • Vaccine against viruses • Vaccines against influenza virus • Universal influenza virus vaccine Competitive Advantages: • Broad protection to both seasonal and pandemic-potential influenza viruses • Easy and cost-effective inactivation method • Effective immune response due to the use of authentic viral antigens • Animal data available Development Stage: • In vivo (animal) Inventors: Jeffery K. Taubenberger, M.D., Ph.D., (NIAID) and Louis Merican Schwartzman, Ph.D. (NIAID). Publications: None. Intellectual Property: HHS Reference No. E–033–2018/0—PCT Application filed January 18, 2019—PCT/US2019/ 014220. Licensing Contact: To license this technology, please contact Jenish Patel, Ph.D., 240–669–2894; jenish.patel@ nih.gov. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is also seeking statements of capability or interest from parties interested in collaborative research. NIAID would like a prospective collaborator to have the capacity to generate clinical grade materials and perform clinical studies. NIAID will consider executing a Confidentiality Agreement with a prospective collaborator to facilitate receipt of a Capability Statement if requested. For collaboration opportunities, please contact Jenish Patel, Ph.D., 240–669–2894; jenish.patel@nih.gov. Dated: November 27, 2019. Wade W. Green, Acting Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2019–26278 Filed 12–4–19; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 66685 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Submission for OMB Review; 30-Day Comment Request; Autism Spectrum Disorder (ASD) Research Portfolio Analysis, NIMH AGENCY: National Institutes of Health, HHS. ACTION: Notice. In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below. DATES: Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication. SUMMARY: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, OIRA_submission@omb.eop.gov or by fax to 202–395–6974, Attention: Desk Officer for NIH. FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: The Office of Autism Research Coordination, NIMH, NIH, Neuroscience Center, 6001 Executive Boulevard, MSC 9663, Room 6184, Bethesda, Maryland 20892 or can email your request, including your address to: iaccpublicinquiries@ mail.nih.gov or nimhprapubliccomments@mail.nih.gov. Formal requests for additional plans and instruments must be requested in writing. ADDRESSES: This proposed information collection was previously published in the Federal Register on October 3, 2019, page 52888 (84 FR 52888) and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Institute of Mental Health (NIMH), National Institutes of Health, may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or SUPPLEMENTARY INFORMATION: E:\FR\FM\05DEN1.SGM 05DEN1

Agencies

[Federal Register Volume 84, Number 234 (Thursday, December 5, 2019)]
[Notices]
[Page 66685]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-26278]



[[Page 66685]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Jenish Patel, Ph.D., 240-669-2894; 
[email protected]. Licensing information and copies of the U.S. 
patent application listed below may be obtained by communicating with 
the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Broadly Protective Influenza Vaccine Comprising a Cocktail of 
Inactivated Avian Influenza Viruses

    Description of Technology: There is a great need for broadly 
protective, ``universal'' influenza virus vaccines given the antigenic 
drift and shift of influenza viruses and the variable protective 
efficacy of the current influenza vaccines. This technology relates to 
a broadly protective, ``universal'' influenza vaccine candidate 
composed of a cocktail of different low pathogenicity avian influenza 
virus subtypes inactivated by betapropiolactone (BPL). Vaccinating 
animals with BPL-inactivated whole virus vaccine comprising influenza 
virus strains belonging to four or more different low pathogenicity 
avian influenza hemagglutinin subtypes, intranasally or 
intramuscularly, provided extremely broad protection and heterosubtypic 
protection to lethal challenge with influenza viruses in both mice and 
ferrets. This influenza vaccine technology has a great potential to 
offer broad protection against both seasonal and pandemic-potential 
influenza viruses.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
    Potential Commercial Applications:

 Vaccine against viruses
 Vaccines against influenza virus
 Universal influenza virus vaccine

    Competitive Advantages:

 Broad protection to both seasonal and pandemic-potential 
influenza viruses
 Easy and cost-effective inactivation method
 Effective immune response due to the use of authentic viral 
antigens
 Animal data available

    Development Stage:

 In vivo (animal)

    Inventors: Jeffery K. Taubenberger, M.D., Ph.D., (NIAID) and Louis 
Merican Schwartzman, Ph.D. (NIAID).
    Publications: None.
    Intellectual Property: HHS Reference No. E-033-2018/0--PCT 
Application filed January 18, 2019--PCT/US2019/014220.
    Licensing Contact: To license this technology, please contact 
Jenish Patel, Ph.D., 240-669-2894; [email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is also seeking statements of 
capability or interest from parties interested in collaborative 
research. NIAID would like a prospective collaborator to have the 
capacity to generate clinical grade materials and perform clinical 
studies. NIAID will consider executing a Confidentiality Agreement with 
a prospective collaborator to facilitate receipt of a Capability 
Statement if requested. For collaboration opportunities, please contact 
Jenish Patel, Ph.D., 240-669-2894; [email protected].

    Dated: November 27, 2019.
Wade W. Green,
Acting Deputy Director, Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases.
[FR Doc. 2019-26278 Filed 12-4-19; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.